Abstract
Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α / ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand , and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.
Keywords: hepatitis c virus, interferon-a, ribavirin, b iymphocytes, endotoxins
Current Pharmaceutical Design
Title: The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells
Volume: 10 Issue: 17
Author(s): L. Amati, R. Cozzolongo, O. G. Manghisi, R. Cuppone, N. M. Pellegrino, D. Caccavo and E. Jirillo
Affiliation:
Keywords: hepatitis c virus, interferon-a, ribavirin, b iymphocytes, endotoxins
Abstract: Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α / ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand , and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.
Export Options
About this article
Cite this article as:
Amati L., Cozzolongo R., Manghisi G. O., Cuppone R., Pellegrino M. N., Caccavo D. and Jirillo E., The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells, Current Pharmaceutical Design 2004; 10 (17) . https://dx.doi.org/10.2174/1381612043384231
DOI https://dx.doi.org/10.2174/1381612043384231 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preclinical Models to Study Breast Cancer
Clinical Cancer Drugs Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Antitumor Pharmacology - Quo Vadis ?
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Multifunctional Lipid-Based Nanocarriers for Image-Guided Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Antibody-Based Preventive and Therapeutic Strategies Against HIV
Current HIV Research Molecule of the Month
Current Topics in Medicinal Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets Molecular Docking and 3D-QSAR Studies on Quinolone-based HDAC Inhibitors
Letters in Drug Design & Discovery Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Current Medicinal Chemistry Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
MicroRNA What Western Pharmacists Need to Know About Traditional Chinese Medicine; A Canadian Perspective
Current Traditional Medicine IL-15 and HIV Infection: Lessons for Immunotherapy and Vaccination
Current HIV Research Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design